$ALAB

ALBA MANUEL sold $3.9M of ALAB (indirect holdings)

ALBA MANUEL sold 8,491 indirectly-held shares of Astera Labs, Inc. (ALAB) at an average of $458.38 ($451.96–$467.99, $3.89M total) across 16 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ALBA MANUEL
Published Jul 7, 2026, 1:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The disclosed fact is the transaction size ($3.89M) and the sale window/price range (~$452–$468). This can modestly affect short-term sentiment but does not, by itself, change the company’s outlook.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The filing does not disclose reasons for the sale; without concurrent operational/financial updates, the signal is mostly sentiment/positioning rather than fundamentals.

Relevance 5/10Novelty 5/10Timing: Filed July 6 for a July 1 sale (pre-arranged 10b5-1)

Background

The article is an SEC Form 4 insider transaction: a director reports an open-market sale of ALAB shares under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs director Alba Manuel sold $3.89M of ALAB shares via a 10b5-1 plan, with 8,491 shares sold at ~$452–$468.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Minimal—this is company-specific insider activity with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Because the sale is 10b5-1, it may reflect scheduled liquidity needs rather than negative expectations; traders may ignore it unless volume/price action suggests otherwise.

Key entities

  • Astera Labs, Inc.

    Company whose director reported a Form 4 open-market sale under a 10b5-1 plan.

  • Alba Manuel

    Director who sold 8,491 shares (indirect holdings) for ~$3.89M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

Astera Labs Stock Fell 9% in a Day as an OpenAI Revenue Report Hit Chip Stocks. Here’s Where the Stock Could Go by 2030

Astera Labs (ALAB) stock dropped 9.21% to $347.05 on October 8, following a broader chip sector sell-off triggered by OpenAI's lower-than-expected revenue report. The company launched Aries 7, its PCIe 7 signal conditioning portfolio. Despite a 23% rise in 2026 revenue forecasts to $1.91B, free cash flow fell 49.6% YoY to $67.21M, raising concerns. Analysts' target prices range from $390 to $850, with a potential total return of 146%.

$ALABMed

Why is Astera Labs stock sliding today?

Astera Labs (ALAB) stock dropped 5.0% after Zacks Research downgraded it from 'strong buy' to 'hold', following a 10% surge on S&P 500 inclusion speculation. Insider selling and high valuation also pressured the stock, with broader market declines adding to the downturn. Competitors like Marvell Technology intensify the competitive landscape. The stock remains sensitive to macroeconomic factors and analyst commentary.

$ALABHigh

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 9.5% to $396.82, with traders anticipating its inclusion in the S&P 500. The company reported Q2 revenue of $392.4M, beating estimates, and guided Q3 revenue to $540M–$560M. Analysts, including Fubon, have upgraded the stock, with a $500 price target. The S&P 500 and Nasdaq each rose 0.7% today.

$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.